Growth hormone and growth hormone binding protein in human urine  by Hattori, Naoki et al.
Kidney International, Vol. 37 (1990), PP. 951—954
Growth hormone and growth hormone binding protein in
human urine
NAOKI HATTORI, AKI1t, SHIMATSU, YUZURU KATO, and HIRoo IMURA
Second Division, Department of Internal Medicine, Kyoto University Faculty of Medicine, Kyoto 606, and the First Division, Department of
Internal Medicine, Shimane Medical University, Izumo 693, Japan
Growth hormone and growth hormone binding protein in human urine.
The presence of growth hormone binding protein (GH-BP) in urine was
demonstrated in normal subjects. Scatchard analysis showed that an
association constant (Ka) and a maximum binding capacity (Bmax) of
urinary GH-BP were 2.3 0.8 x 108 M1 and 19.2 4.0 ng/mg urinary
protein, respectively. The molecular weight of the urinary GH-BP was
estimated to be 50000 to 70000 on gel chromatography. Although the
molecular weight and Ka were similar to those of plasma GHBP, Bmax
of urinary GH-BP was significantly higher than that of plasma GH-BP
(0.44 0.12 ng/mg protein). GH-BP in urine may be derived from
plasma and/or renal tubules.
The kidney plays an important role in the catabolism of
circulating growth hormone [1, 2]. Growth hormone is exten-
sively filtrated through glomerulus, subsequently absorbed at
the proximal tubules and catabolized within renal tubular cells
[1]. Human growth hormone (GH) in plasma is heterogenous [3]
and composed of monomeric and high molecular weight forms
on gel chromatography [4, 5]. The "big" forms are attributed to
oligomers of GH [61 and a complex of GH with specific OH
binding protein (GH-BP), which was recently characterized
[7—9]. We have previously demonstrated that urinary GH mea-
sured by highly sensitive enzyme immunoassay (EIA) is mainly
composed of monomeric form [21. In the present study, we
further investigated the molecular forms of GH and demon-
strated the presence of GH-BP in urine.
Methods
Samples
Blood samples were obtained by venipuncture at 08.00 hours
after an overnight fasting from five normal men (aged 31 to 40
yr). Plasma was promptly separated and kept at —20°C. Urine
samples were collected during nighttime from 00.00 hours to
08.00 hours and immediately dialyzed against 0.01 mol/liter
sodium phosphate buffer (pH 7.0) containing 0.1 mol/liter NaCl
and 0.1% NaN3 at 4°C overnight. A part of the dialyzed urine
was concentrated 50-fold with 10% polyethylene glycol and
kept at 4°C for binding studies. Protein and albumin levels in
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urine before concentration were 76 14 mg/liter and 3.5 1.3
mg/liter, respectively.
Assays
Native GH was measured by ultrasensitive enzyme immu-
noassay (EIA) as previously described [10]. In brief, plasma or
dialyzed urine samples were incubated with anti-GH IgO-
coated polystyrene balls (Precision Plastic Ball Co., Chicago,
Illinois, USA) at 37°C for six hours. The polystyrene balls were
washed with saline and further incubated with affinity-purified
anti-OH Fab'-peroxidase conjugate at 4°C for 16 hours and then
20°C for six hours. After washing, the peroxidase activity
bound to the polystyrene balls were assayed by enzymatic
reaction with 3-(p-hydroxyphenyl) propionic acid (Aldrich
Chemical Co., Milwaukee, Wisconsin, USA) for 90 minutes at
30°C. Fluorescence intensity was measured by a spectrofluoro-
photometer (Shimadzu Co., Kyoto, Japan). The minimum
detectable quantity of OH was 30 fg/tube. The intra- and
interassay coefficients of variation were 6.0% and 8.6%, respec-
tively.
Protein concentrations of plasma and dialyzed urine were
determined by the methods of Biuret [11] and Lowry et al [12],
respectively. Urinary albumin was measured by a commercial
radioimmunoassay kit (Eiken Kagaku Co., Tokyo, Japan).
Binding studies
Plasma or dialyzed and concentrated urine samples (200 pi)
were incubated with monomeric '251-GH (20,000 cpm/20 d;
about 0.4 ng) and varying amounts of unlabeled GH (0.3 to 100
ngI2O l) for 90 minutes at 37°C. At the end of the incubation
period, the mixture was immediately subjected to gel chroma-
tography at 4°C. Separation of bound from free OH was
performed by gel filtration on an Ultrogel AcA44 analytical
column (0.9 x 70 cm) for the determination of molecular
weights and on an Ultrogel AcA44 minicolumn (0.9 X 25 cm) for
binding studies. The analytical column was calibrated with
molecular weight markers. Samples were eluted with 0.01
mol/liter sodium phosphate buffer (pH 7.0) containing 0.1
mol/liter NaC1 and 0.1% NaN3 at 4°C, and the radioactivity of
each fraction was counted by auto-gamma counter (ALOKA,
Tokyo, Japan). Fractions of 0.6 ml were collected at the flow
rate of 0.1 ml/min for the analytical column and of 0.2 mI/mm
for the minicolumn. Nonspecific binding was calculated after
incubation of plasma or urine with '251-GH in the presence of
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Table 1. GH and GH binding protein in urine and plasma in normal subjects
Urine Plasma
Case
GHa
/Lg/liter
GH-BP
OH
p,g/liter
GH-BP
Ka
)<
Bm.,,
ng/mg protein
Ka
X
Bn,ax
ng/mg protein
1
2
3
4
5
Mean SE
0.004
0.009
0.007
0.006
0.005
0.006 0.001
2.5
5.3
1.8
1.0
1.0
2.3 0.8
23.7
4.6
17.6
27.3
22.9
19.2 4.0
0.14
0.11
0.23
0.18
0,20
0.17 0.04
2.1
1.4
2.2
3.5
1.7
2.2 0.4
0.67
0.39
0.37
0.32
0.43
0.44 0.12
a Endogenous urinary OH levels before concentration
1500
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excess unlabeled GH (I mg/liter). Dialyzed and concentrated
urine (200 d) samples were treated with 1% trypsin (DIFCO
Lab. Detroit; 20 1.d) for 60 minutes at 37°C and the digestion was
stopped by the addition of 1% soybean trypsin inhibitor type I-S
(20 pi; Sigma Chemical Co., ST Louis, Missouri, USA). The
trypsin-digested samples were also used for binding studies.
Drugs
GH (HS2243E, NHPP) used for standards and for iodination
was from the National Hormone and Pituitary Program (Balti-
more, Maryland, USA). GH was iodinated using lactoperoxi-
dase method as previously described [13]. Specific activity was
calculated as about 50 Ci/j.tg. All other reagents were obtained
as previously described [10].
Statistical analysis
The amount of bound GH was expressed as a percentage of
total GH recovered. The results of binding studies were ana-
Fig. 1. Gel filtration profiles of '251-GH
bound with plasma and urine. Normal plasma
and dialyzed and concentrated urine (200 s.d),
containing 0.17 tg/liter and 0.30 pg/liter
endogenous OH, respectively, were incubated
with 20000 cpm (about 0.4 ng) of '251-GH in
the presence (0) or in the absence (•) of
excess unlabeled OH (1 mg/liter) at 37°C for
90 minutes and were subjected to gel filtration
100 using an Ultrogel AcA 44 column (0.9 x 70
cm) at 4°C. Arrows indicate the elution
positions of void and monomeric GH.
lyzed by Scatchard analysis. The data were expressed as means
SEM. Student's t-test was used for statistical analysis.
Results
Mean endogenous OH levels in plasma and urine samples
measured by EIA were 0.17 0.04 (± SEM) p,g/liter and 0.006
0.001 p,g/liter, respectively, as shown in Table 1. The
amounts of endogenous GH in plasma and urine were so little
that they did not interfere '251-GH binding to GH-BP.
The binding of '251-GH with plasma or urine is shown in
Figure 1. Four peaks of radioactivity were identified in the case
of plasma. First peak eluted at the void volume was not
abolished by adding excess unlabeled GH, while the second
peak with molecular weight of 70,000 to 90,000 was displaced
by excess unlabeled GH. Third and fourth peaks represent
monomeric OH and free 1251 respectively, as previously de-
scribed [7, 8]. In the case of urine, no apparent peak was
observed at the void volume. The peak of "big" OH corre-
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sponding to molecular weight of 70,000 to 90,000 was observed.
'251-GH binding to "big" fraction was dose-dependently inhib-
ited by the addition of unlabeled GH, suggesting the existence
of GH-BP in urine. Complex of GH and GH-BP was not
observed in urine after trypsin digestion (% of complex: trypsin-
digested urine; 0.8 0.1 % vs. control urine; 32.4 4.1 %, P <
0.001).
The binding characteristics of GH-BP in urine and plasma
were analyzed by Scatchard analysis. The association constant
(Ka) of GH-BP in urine (2.3 0.8 x 108 M) was not
significantly different from that in plasma (2.2 0.4 x 108 MI;
Table 1, Fig. 2). The maximum binding capacity (Bmax) of
urinary GH-BP was 1.2 0.3 ng/ml of unaltered urine. When
the Bmax of urinary GH-BP was expressed as ng per mg protein,
it was significantly higher than that of plasma GH-BP (19.2
4.0 vs. 0.44 0.12 nglmg protein, P < 0.01).
To examine whether GH binding is demonstrable with native
GH, we conducted similar experiments with unlabeled GH. Fig.
3 shows the elution profiles of endogenous OH in dialyzed and
concentrated urine, GH standard (10 ig/1iter), and dialyzed and
concentrated urine supplemented with GH standard (10 ,ag/
liter). OH was determined in each fraction by EIA. It is obvious
that in the presence of urine, conversion of monomeric GH to
"big" components occurred, consistent with the binding phe-
nomenon.
Discussion
Low molecular weight proteins such as GH are mostly
filtrated through glomerulus and reabsorbed at the proximal
tubules [1, 14]. Approximately 0.003 to 0.025% of plasma OH is
excreted in urine in normal subjects [151. Urinary OH excretion
increases in patients with renal insufficiency and in acromegaly
[2, 10]. We previously demonstrated that urinary OH is mainly
composed of monomeric form, while plasma GH is composed
of monomeric and higher molecular weight forms [2]. "Big"
Fig. 3. Gel filtration profiles of endogenous GH in dialyzed and con-
centrated urine (Lx), GH standard (10 pgIliter) (0) and dialyzed and
concentrated urine supplemented with GH standard (10 glliter) (•).
Endogenous GH level in urine was 0.004 glliter before concentration.
Dialyzed and concentrated urine (200 s.d) was supplemented with native
GH (2 ng/20 d) and incubated at 37°C for 90 minutes, followed by gel
filtration on an Ultrogel AcA 44 minicolumn (0.9 x 25 cm) at 4°C.
forms of OH in plasma are partly attributed to the complex of
OH with OH-BP [7—9].
Our initial attempt of simply adding exogenous GH to fresh
urine failed to show OH-binding in urine. However, in the
present study, we could demonstrate GH binding protein in
dialyzed and concentrated urine by removing urea which hin-
ders binding of OH [161. To exclude the hazardous effect of
using iodinated OH as a ligand, we performed a binding study
using native OH and obtained similar results.
Calculated molecular weight and Ka values of urinary OH-BP
were similar to those of plasma GH-BP, which were compatible
with those reported previously (molecular weight:50,000 to
85,000, Ka:2 to 3 x 108 M1) [7—9]. Of interest is that Bm 0f'
urinary OH-BP was extremely higher than that of plasma
GH-BP. Although we cannot directly measure the amount of
OH-B P at the present time, the proportion of GH-BP in urinary
protein is much higher than that in plasma protein. Albumin, a
15
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Fig. 2. Saturation curve and Scatchard plots of '251-GH specific bind-
ing with urinary GH-BP from a normal subject. The concentration of
urinary protein was 3.2 g/liter.
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major protein in plasma, constituted only 5% of urinary protein
in the present study. Urinary protein other than albumin is
composed of different plasma proteins and of glycoproteins that
derived from renal tubular cells 1171. High proportion of GH-BP
in urinary protein cannot be explained by size selectivity since
the molecular weight of urinary GH-BP and albumin is similar.
GH-BP may have different charge properties from albumin and
is filtrated from plasma through glomerulus more easily or not
be subjected to reabsorption at the tubules. Another possibility
is that GH-BP in urine may be derived from GH receptors shed
from the renal tubules since GH-BP in plasma has been recently
shown to be derived from GH receptors [9]. Further studies are
needed to explore the significance of GH-BP in urine.
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